实用肿瘤学杂志 ›› 2010, Vol. 24 ›› Issue (3): 234-237.doi: 10.3969/j.issn.1002-3070.2010.03.010

• 论著 • 上一篇    下一篇

89Sr治疗骨转移瘤后韧致辐射显像的临床应用

姜季, 荣国艳, 王兴华, 崔亚利   

  1. 哈尔滨医科大学附属肿瘤医院核医学科(哈尔滨 150081)
  • 收稿日期:2010-03-25 出版日期:2010-06-28 发布日期:2015-01-24
  • 通讯作者: 崔亚利,E-mail:jiangjiufo@163.com
  • 作者简介:姜季,女,(1981-),硕士,从事肿瘤核医学的治疗

Therapeutic evaluation on bremsstrahlung imaging after 89Sr administration in patients with bone metastases

JIANG Ji, RONG Guoyan, WANG Xinghua, CUI Yali   

  1. The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081
  • Received:2010-03-25 Online:2010-06-28 Published:2015-01-24

摘要: 目的 探讨应用韧致辐射原理显像,并监测放射性药物89Sr治疗骨转移瘤后在患者体内的吸收分布情况及判断预后的可行性。方法 经静脉注射放射性药物89Sr的患者于治疗后1周进行韧致辐射显像,并与89Sr治疗前所进行的99mTc-亚甲基二膦酸盐(MDP)骨显像所得的图像进行对比。然后勾划感兴趣区(ROI)计算摄取最浓的病灶处和对侧或周围正常部位的放射性比值(T/NT比值)。并随访其疼痛缓解程度。结果 89Sr韧致辐射显像与99mTc-MDP骨显像对照,所发现的病灶浓聚部位基本吻合。但与后者相比,89Sr韧致辐射显像图像分辨率较差且解剖部位亦显示不佳,尤其是肋骨、小病灶处和99mTc-MDP显像所示的放射性轻度浓聚灶。计算所得的T/NT比值约为3.13±1.03(1.24-5.81)。在后期随访中,89Sr韧致辐射显像中T/NT比值较高的患者,其疼痛等症状缓解程度也较为明显。结论 利用韧致辐射原理进行显像能够监测纯β发射体放射性核素89Sr在患者体内的分布情况,并可以通过计算T/NT比值,再佐以患者疼痛的缓解程度可以初步判读预后情况。

关键词: 骨转移瘤, 放射性核素锶-89(89Sr), 韧致辐射显像, 放射性核素治疗

Abstract: Objective To explore and analyze imaging by bremsstrahlung phenomenon after 89Sr administration in patients with bone metastases.And then monitoring distribution of the bone-seeking radiopharmaceutical 89Sr in body and evaluating the feasibility of the method.Methods Bremsstrahlung imaging was performed in 15 patients in the 7th day after 89Sr administration and there was comparision between it and 99mTc-methylene bisphosphonate(MDP)bone scans.The region of interest(ROI)was outlined and then target/non-target ratio(T/NT ratio)was calculated.And a follow-up was made to observe thesis ache alleviation degree.Results Images gotten by 89Sr bremsstrahlung imaging are similar to those by 99mTc-MDP bone imaging,but the image reslution is less than the latter.T/NT ratio was about 3.13±1.03(1.24-5.81).Conclusion With skeletal metastases through calculating T/NT ratio,and with pain relief degree,89Sr bremsstrahlung imaging for monitoring distribution of the bone-seeking radiopharmaceutical 89Sr in body is feasibility.And it can preliminary decide prognosis of the patients.

Key words: Bone metastases, Strontium-89(89Sr)radionuclide, Bremsstrahlung imaging, Radionuclide therapy

中图分类号: